Saturday, October 31, 2026

GBP/EUR Bullish Momentum: 0.84% Up In The Last 5 Sessions

GBP/EUR Bullish Momentum: 0.84% Up In The Last 5 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 0.84% for the last 5 sessions. At 20:07 EST on Wednesday, 5 July, GBP/EUR (GBPEUR) is $1.17.

GBP/EUR's yearly highs and lows, it's 8.212% up from its 52-week low and 2.402% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was 0.21%, 0.06%, and 0.25%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.39% (last week), 0.28% (last month), and 0.25% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be oversold (<=20).

News about

  • Eur/usd price analysis: euro slips to 1.0900 on Monday’s doji, downbeat MACD signals. According to FXStreet on Tuesday, 4 July, "In a case where the EUR/USD remains bearish past 1.0865, Friday's bottom of 1.0835 can act as the final defense of the Euro bulls.", "With this, the EUR/USD price appears well-set to prod a five-week-old rising support line, near 1.0870. "
  • Eur/usd trades with a mild positive amid subdued USD demand, remains below 1.0900. According to FXStreet on Wednesday, 5 July, "This, in turn, is seen as a key factor that continues to lend some support to the shared currency, which, along with subdued US Dollar (USD) price action, provides a modest boost to the EUR/USD pair.", "The EUR/USD pair attracts some buying during the Asian session on Wednesday and recovers a part of the previous day's modest losses. "
  • Eur/usd forex signal: selling off from resistance area above $1.0920 - 04 July 2023. According to DailyForex on Tuesday, 4 July, "My previous EUR/USD signal on 26th June was not triggered, as the bullish price action took place a bit below the support level identified at $1.0899.", "In my previous analysis of the EUR/USD currency pair on Monday last week, I wrote that the technical picture had become bullish, but also that as the support level at $1.0899 was very confluent with a round number, there could be a long scalping opportunity here, but the price was unlikely to move much."
  • Eur/usd corrects to near 1.0900 as focus shifts to FOMC minutes and eurozone retail sales. According to FXStreet on Tuesday, 4 July, "The EUR/USD pair has corrected to near the round-level cushion of 1.0900 in the late Asian session. "
  • Eur/usd technical analysis: moving in narrow ranges - 04 July 2023. According to DailyForex on Tuesday, 4 July, "I expect the EUR/USD to continue moving in narrow ranges until the markets and investors react to the announcement of the contents of the minutes of the last meeting of the Federal Reserve Bank, and then the US job numbers.", " rates suggest EUR/USD selling at 1.05 - and the stock market is arguing buying EUR/USD at 1.10," says Jordan Rochester, forex analyst at Bank Nomura. "

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com